Similarly, in the PAKT trial, Schmid et al. reported that the PFS prolongation observed with Capivasertib plus Paclitaxel versus Paclitaxel plus placebo in triple-negative metastatic BC was mainly driven by the PIK3CA/Akt1/PTEN-altered population, since no beneficial effect from the addition of Capivasertib to Paclitaxel was observed in patients with PIK3CA/Akt1/PTEN non-altered tumors [39]. Here, PTEN is linked to breast cancer.